Early Detection of Cardiac Damage by Two-Dimensional Speckle Tracking Echocardiography After Thoracic Radiation Therapy: Study Protocol for a Prospective Cohort Study

Dan Zhu, Tingcui Li, Hongqing Zhuang, Ming Cui, Dan Zhu, Tingcui Li, Hongqing Zhuang, Ming Cui

Abstract

Background: As one of the important treatment methods for cancer patients, radiotherapy may lead to incidental irradiation of the heart, resulting in radiotherapy-induced heart disease (RIHD) arising many years after radiotherapy. While, there are few studies on early subclinical cardiac damage, which may be essential for the protection of late RIHD. To detect and predict RIHD and early subclinical cardiac damage induced by thoracic radiation therapy, based on two-dimensional speckle tracking echocardiography (2D STE) combined with multiple circulating biomarkers and accurate heart dosimetry.

Methods and analysis: This is a monocentric prospective cohort study in which 104 patients treated for malignant tumors and with cardiac radiation exposure will be included. All participants will be followed for 12 months after radiotherapy. Echocardiography, 2D STE, and blood samples will be underwent at 5-time points (baseline; after completion of RT; 2, 6, and 12 months after RT). Left ventricular ejection fraction (LVEF); global longitudinal, radial, and circumferential strain; diastolic function parameters; creatine kinase (CK); creatine kinase isoenzyme (CK-MB); cardiac troponin T (cTnT); N-terminal pro-B-type natriuretic peptide (NT-proBNP) and hypersensitive C-reactive protein (hs-CRP) will be measured at baseline and every follow-up time. The incidence of major adverse cardiovascular events will be recorded.

Discussion: This study details the protocol and presents the primary limits and advantages of this single-center project. The inclusion of patients began in 2021, and the results are expected to be published in 2023. This study will be allowed to enhance knowledge on detection and prediction of early subclinical cardiac dysfunction induced by thoracic radiation therapy, based on two-dimensional speckle tracking echocardiography (2D STE) combined with circulating biomarkers and accurate heart dosimetry. Furthermore, we will evaluate risk factors of subtle cardiac damage and identify high-risk groups for early heart damage.

Clinical trial registration: ClinicalTrials.gov, identifier: NCT04443400.

Keywords: biomarkers; cardiotoxicity; radiotherapy; radiotherapy-induced heart disease; two-dimensional speckle tracking echocardiography.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Zhu, Li, Zhuang and Cui.

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. 10.3322/caac.21492
    1. The The L GLOBOCAN . 2018: counting the toll of cancer. Lancet. (2018) 392:985. 10.1016/S0140-6736(18)32252-9
    1. Al-Kindi SG, Oliveira GH. Incidence and trends of cardiovascular mortality after common cancers in young adults: analysis of surveillance, epidemiology and end-results program. World J Cardiol. (2016) 8:368–74. 10.4330/wjc.v8.i6.368
    1. Kesson EM, Allardice GM, George WD, Burns HJ, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ. (2012) 344:e2718. 10.1136/bmj.e2718
    1. Wang H, Wei J, Zheng Q, Meng L, Xin Y, Yin X, et al. . Radiation-induced heart disease: a review of classification, mechanism and prevention. Int J Biol Sci. (2019) 15:2128–38. 10.7150/ijbs.35460
    1. Lewis GD, Farach A. Cardiovascular toxicities of radiation therapy. Methodist Debakey Cardiovasc J. (2019) 15:274–81. 10.14797/mdcj-15-4-274
    1. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. . Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. (2005) 366:2087–106. 10.1016/S0140-6736(05)67887-7
    1. Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. (2005) 97:419–24. 10.1093/jnci/dji067
    1. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. (2005) 6:557–65. 10.1016/S1470-2045(05)70251-5
    1. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, et al. . Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. (2013) 368:987–98. 10.1056/NEJMoa1209825
    1. Wennstig AK, Wadsten C, Garmo H, Fredriksson I, Blomqvist C, Holmberg L, et al. . Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer: results from a large population-based cohort. Breast Cancer Res. (2020) 22:10. 10.1186/s13058-020-1249-2
    1. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. (2003) 290:2831–7. 10.1001/jama.290.21.2831
    1. Baker JE, Moulder JE, Hopewell JW. Radiation as a risk factor for cardiovascular disease. Antioxid Redox Signal. (2011) 15:1945–56. 10.1089/ars.2010.3742
    1. Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, et al. . Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. (2011) 79:10–8. 10.1016/j.ijrobp.2009.10.058
    1. Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, et al. . Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. Circ Heart Fail. (2016) 9:e2661. 10.1161/CIRCHEARTFAILURE.115.002661
    1. Yu AF, Ho AY, Braunstein LZ, Thor ME, Lee CK, Eaton A, et al. . Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy. J Am Soc Echocardiogr. (2019) 32:521–8. 10.1016/j.echo.2018.12.009
    1. Trivedi SJ, Choudhary P, Lo Q, Sritharan HP, Iyer A, Batumalai V, et al. . Persistent reduction in global longitudinal strain in the longer term after radiation therapy in patients with breast cancer. Radiother Oncol. (2019) 132:148–54. 10.1016/j.radonc.2018.10.023
    1. Skytta T, Tuohinen S, Luukkaala T, Virtanen V, Raatikainen P, Kellokumpu-Lehtinen PL. Adjuvant radiotherapy-induced cardiac changes among patients with early breast cancer: a three-year follow-up study. Acta Oncol. (2019) 58:1250–8. 10.1080/0284186X.2019.1630751
    1. Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, et al. . Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. (2013) 26:1013–32. 10.1016/j.echo.2013.07.005
    1. Skytta T, Tuohinen S, Boman E, Virtanen V, Raatikainen P, Kellokumpu-Lehtinen PL. Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy. Radiat Oncol. (2015) 10:141. 10.1186/s13014-015-0436-2
    1. Palumbo I, Palumbo B, Fravolini ML, Marcantonini M, Perrucci E, Latini ME, et al. . Brain natriuretic peptide as a cardiac marker of transient radiotherapy-related damage in left-sided breast cancer patients: A prospective study. Breast. (2016) 25:45–50. 10.1016/j.breast.2015.10.004
    1. Zhang C, Shi D, Yang P. BNP as a potential biomarker for cardiac damage of breast cancer after radiotherapy: a meta-analysis. Medicine. (2019) 98:e16507. 10.1097/MD.0000000000016507
    1. Guzhva L, Mendenhall NP, Morris CG, Flampouri S, Hoppe BS. Evaluating cardiac biomarkers after chemotherapy and proton therapy for mediastinal hodgkin lymphoma. Int J Part Ther. (2017) 4:35–8. 10.14338/IJPT-D-17-00022
    1. Canada JM, Thomas GK, Trankle CR, Carbone S, Billingsley H, Van Tassell BW, et al. . Increased C-reactive protein is associated with the severity of thoracic radiotherapy-induced cardiomyopathy. Cardiooncology. (2020) 6:2. 10.1186/s40959-020-0058-1
    1. Akazawa H. Cardiotoxicity of cancer chemotherapy—mechanisms and therapeutic approach. Gan To Kagaku Ryoho. (2017) 44:2058–63.
    1. Avila MS, Siqueira S, Ferreira S, Bocchi EA. Prevention and treatment of chemotherapy-induced cardiotoxicity. Methodist Debakey Cardiovasc J. (2019) 15:267–73. 10.14797/mdcj-15-4-267
    1. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. . ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. (2000) 36:970–1062. 10.1016/s0735-1097(00)00889-5
    1. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol. (2017) 70:2552–65. 10.1016/j.jacc.2017.09.1095
    1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. . Third universal definition of myocardial infarction. J Am Coll Cardiol. (2012) 60:1581–98. 10.1016/j.jacc.2012.08.001
    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. (2016) 37:2129–200. 10.1093/eurheartj/ehw128
    1. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. . 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. (2014) 63:e57–185. 10.1016/j.jacc.2014.02.536
    1. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. . 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. (2015) 36:2921–64. 10.1093/eurheartj/ehv318
    1. Tembhekar AR, Wright CL, Daly ME. Cardiac dose and survival after stereotactic body radiotherapy for early-stage non-small-cell lung cancer. Clin Lung Cancer. (2017) 18:293–8. 10.1016/j.cllc.2016.12.007
    1. Lebesque JV, Keus RB. The simultaneous boost technique: the concept of relative normalized total dose. Radiother Oncol. (1991) 22:45–55. 10.1016/0167-8140(91)90068-r
    1. Joiner MC, Bentzen SM. Fractionation: the linear quadratic approach. Basic Clin Radiobiol. (2018) 8:102–19.
    1. Stam B, Peulen H, Guckenberger M, Mantel F, Hope A, Werner-Wasik M, et al. . Dose to heart substructures is associated with non-cancer death after SBRT in stage I-II NSCLC patients. Radiother Oncol. (2017) 123:370–5. 10.1016/j.radonc.2017.04.017
    1. Xiao Y, Papiez L, Paulus R, Timmerman R, Straube WL, Bosch WR, et al. . Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. (2009) 73:1235–42. 10.1016/j.ijrobp.2008.11.019
    1. Tarantini L, Gulizia MM, Di Lenarda A, Maurea N, Giuseppe AM, Bisceglia I, et al. . ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summary. Eur Heart J Suppl. (2017) 19:D370–9. 10.1093/eurheartj/sux019
    1. Tsai HR, Gjesdal O, Wethal T, Haugaa KH, Fossa A, Fossa SD, et al. . Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy. Am J Cardiol. (2011) 107:472–7. 10.1016/j.amjcard.2010.09.048

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever